Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sibrotuzumab-IR700DX
- Development stage
- Preclinical
- Lead developer
- Boehringer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sibrotuzumab-IR700DX is an antibody-photosensitizer conjugate (APC) designed for near-infrared photoimmunotherapy (NIR-PIT). It consists of the humanized monoclonal antibody sibrotuzumab, which targets fibroblast activation protein (FAP), conjugated to the photosensitizer IRDye700DX. This therapeutic agent is designed to selectively target and eliminate FAP-expressing cancer-associated fibroblasts (CAFs) within the tumor microenvironment. Upon exposure to near-infrared light, the IR700DX moiety induces rapid, selective cell death of the targeted CAFs, which can lead to the remodeling of the extracellular matrix and improved delivery of co-administered chemotherapeutic agents. Preclinical studies in esophageal cancer models have demonstrated its potential to overcome drug resistance by reducing interstitial pressure and enhancing drug penetration.
- Other names
- Sibrotuzumab-IR700Sibrotuzumab-IR-700Sibrotuzumab-IR 700Sibrotuzumab-IRDye700DXSibrotuzumab-IRDye-700DXSibrotuzumab-IRDye 700DX
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on sibrotuzumab-IR700DX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sibrotuzumab-IR700DX.